|
|
|
|
| LEADER |
00000cam a2200000Mi 4500 |
| 001 |
SCIDIR_on1405395108 |
| 003 |
OCoLC |
| 005 |
20231120010756.0 |
| 006 |
m o d |
| 007 |
cr cnu|||||||| |
| 008 |
231019s2023 cau o 000 0 eng d |
| 040 |
|
|
|a SFB
|b eng
|e rda
|e pn
|c SFB
|d OPELS
|d OCLCO
|
| 066 |
|
|
|c (S
|
| 020 |
|
|
|z 9780443294686
|
| 020 |
|
|
|z 0443294682
|
| 035 |
|
|
|a (OCoLC)1405395108
|
| 050 |
|
4 |
|a RC386.2
|
| 082 |
0 |
4 |
|a 616.8
|
| 245 |
0 |
0 |
|a Nanowired delivery of drugs and antibodies for neuroprotection in brain diseases with co-morbidity factors.
|n Part B /
|c edited by Hari Shanker Sharma, Lars Wiklund, Aruna Sharma.
|
| 250 |
|
|
|a 1st ed.
|
| 264 |
|
1 |
|a San Diego :
|b Elsevier Science & Technology,
|c 2023.
|
| 264 |
|
4 |
|c �2024.
|
| 300 |
|
|
|a 1 online resource (313 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a International review of neurobiology ;
|v v. 172
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources.
|
| 505 |
0 |
|
|a Intro -- Title page -- Table of Contents -- Series Page -- Copyright -- Contributors -- Preface -- References -- Acknowledgements -- Section 1 Spinal cord Injury -- Chapter One: Spinal cord injury induced exacerbation of Alzheimer's disease like pathophysiology is reduced by topical application of nanowired cerebrolysin with monoclonal antibodies to amyloid beta peptide, p-tau and tumor necrosis factor alpha -- Abstract -- 1 Introduction -- 2 Spinal cord injury and Alzheimer's disease -- 3 Our observation on spinal cord injury and Alzheimer's disease pathology -- 4 Spinal cord injury and blood-spinal cord barrier -- 5 Possible mechanism of neuroprotection in spinal cord injury -- 6 Conclusion and future perspectives -- References -- Chapter Two: Nanodelivery of histamine H3 receptor inverse agonist BF-2649 with H3 receptor antagonist and H4 receptor agonist clobenpropit induced neuroprotection is potentiated by antioxidant compound H-290/51 in spinal cord injury -- Abstract -- 1 Introduction -- 2 Nanowired delivery of H-290/51 with histaminergic H3 and H4 receptor modulators in spinal cord injury -- 3 Our observations in spinal cord injury -- 4 Blood-spinal cord barrier in spinal cord injury -- 5 Spinal cord edema and volume swelling in spinal cord injury -- 6 Spinal cord blood flow in spinal cord injury -- 7 Oxidative stress parameters in spinal cord injury -- 8 Neuropathology of spinal cord injury -- 9 Molecular markers of neuropathology in spinal cord injury -- 10 Possible mechanisms of neuroprotection in spinal cord injury -- Acknowledgments -- References -- Chapter Three: Neuromodulation and quality of life for patient with spasticity after spinal cord injury -- Abstract -- 1 Introduction -- 2 Materials and methods -- 3 Results -- 4 Discussion -- References -- Section 2 Neurodegenerative disease.
|
| 505 |
8 |
|
|a Chapter Four: Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment -- Abstract -- 1 Introduction -- 2 Nanoparticle-drug delivery systems in PD therapeutics -- 3 Enriched environment as non-invasive strategy for PD treatment -- 4 Synergistic effect of an enriched environment and nanodelivery administration -- 5 Concluding remarks -- References -- Chapter Five: Co-administration of DL-3-n-butylphthalide and neprilysin is neuroprotective in Alzheimer disease associated with mild traumatic brain injury -- Abstract -- 1 Introduction -- 2 Methodological consideration -- 3 Our observations on nanowired DL-3-n-butylphthalide in Alzheimer's disease -- 4 Possible mechanisms of DL-3-n-butylphthalide in neuroprotection in Alzheimer's disease -- Acknowledgments -- References -- Section 3 Drugs of abuse and neurotoxicity -- Chapter Six: Nicotine neurotoxicity exacerbation following engineered Ag and Cu (50-60 nm) nanoparticles intoxication. Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetron -- Abstract -- 1 Introduction -- 2 Our observations on metal nanoparticles exposure and nicotine neurotoxicity -- 3 Observations on nicotine neurotoxicity with nanoparticles exposure -- 4 Molecular markers of neuroinflammation -- 5 Molecular markers of oxidative stress -- 6 Possible mechanisms of neuroprotection in nicotine neurotoxicity -- Acknowledgments -- References -- Section 4 Clinical neurology and oncology -- Chapter Seven: Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention -- Abstract -- 1 Introduction -- 2 Description of the proposed technology.
|
| 650 |
|
0 |
|a Brain
|x Diseases
|x Treatment.
|
| 650 |
|
0 |
|a Drug delivery systems.
|
| 650 |
|
0 |
|a Nanowires.
|
| 650 |
|
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
2 |
|a Nanowires
|0 (DNLM)D053770
|
| 650 |
|
6 |
|a Cerveau
|0 (CaQQLa)201-0001145
|x Maladies
|0 (CaQQLa)201-0001145
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
6 |
|a Syst�emes d'administration de m�edicaments.
|0 (CaQQLa)000260397
|
| 650 |
|
6 |
|a Nanofils.
|0 (CaQQLa)201-0331579
|
| 700 |
1 |
|
|a Sharma, Hari Shanker.
|
| 700 |
1 |
|
|a Wiklund, Lars.
|
| 700 |
1 |
|
|a Sharma, Aruna.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00747742/172
|z Texto completo
|
| 880 |
8 |
|
|6 505-00/(S
|a 3 The method of genomic balancing has two directions -- 4 Scientific substantiation of the proposed technology -- 5 Stages of ex vivo gene therapy -- 6 Gene therapy efficacy evaluation -- 7 Possible complications and the methods to prevent and to reduce them -- 8 The results of preclinical efficiency trial of the proposed gene therapy -- 9 Conclusion -- References -- Chapter Eight: An overview of Twist1 in glioma progression and recurrence -- Abstract -- 1 Introduction -- 2 Structure of the human Twist1 gene and protein -- 3 Regulation mechanism of Twist1 expression -- 4 Twist1 in glioma progression and recurrence -- 5 Discussion and conclusion -- References -- Chapter Nine: A review of traditional Chinese medicine Curcumae Rhizoma for treatment of glioma -- Abstract -- 1 Introduction -- 2 The general principle of TCM treatment and the role of Curcumae Rhizoma -- 3 Bioactive components of Curcumae Rhizoma against glioma -- 4 β-Elemene -- 5 Discussion and conclusion -- References -- Chapter Ten: Case report of epileptic seizure during awake craniotomy of functional area glioma and literature study -- Abstract -- 1 Brief introduction -- 2 Case-reporting -- 3 Discussion -- 4 Tumor character -- 5 Perioperative epileptic seizures -- 6 Intraoperative neuroelectrophysiology -- 7 Other -- 8 Conclusion -- References.
|
